CM
VKTX icon

Caption Management’s Viking Therapeutics VKTX Stock Holding History

Caption Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25M Buy
+100,000
New +$3.21M 0.02% 663
2025
Q4 		– Sell
-76,900
Closed -$2.02M – 2089
2025
Q3 		$2.02M Buy
76,900
+74,100
+2,646% +$2.21M 0.02% 840
2025
Q2 		$74.2K Sell
2,800
-37,200
-93% -$979K ﹤0.01% 1330
2025
Q1 		$966K Buy
+40,000
New +$1.26M 0.01% 929
2024
Q2 		– Sell
-612,500
Closed -$50.2M – 1537
2024
Q1 		$50.2M Buy
612,500
+395,500
+182% +$17.6M 0.76% 21
2023
Q4 		$4.04M Buy
217,000
+90,000
+71% +$1.18M 0.05% 402
2023
Q3 		$1.41M Buy
127,000
+78,800
+163% +$1.13M 0.02% 675
2023
Q2 		$781K Buy
+48,200
New +$1.01M 0.01% 723

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Caption Management's VKTX Position: Q1 2026 in Review

Caption Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 36,880 shares — an estimated $1.19M sold.

Caption Management first reported a position in VKTX in Q1 2019 and held it in 11 quarters. The position peaked at $3.2M in Q1 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Caption Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Caption Management sold 36,880 Viking Therapeutics shares in Q1 2026, an estimated $1.19M.
  • Caption Management first reported a position in Viking Therapeutics in Q1 2019 and held it in 11 quarters.
  • Caption Management's Viking Therapeutics position peaked at $3.2M in Q1 2024.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.